English
banner
Products
Home

Polypeptides

LIRAGLUTIDE 204656-20-2

LIRAGLUTIDE 204656-20-2

  • Product Details

Product Information


Product name

Liraglutide

Sequence

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-

Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-

-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

CAS No.

204656-20-2

Molecular Formula

C172H265N43O51

Molecular Weight

3751.20

Storage

 2~8

Appearance

White to off-white crystalline powder


COA of Liraglutide


Test

Specification

Results

Appearance:

White to off-white crystalline powder or lumps

White powder

Identity:

3751.2±1.0

3751.1

Purity (By HPLC) :

Not Less than 98.0%;

99.51%

Residual solvents:

≤0.25%total; ≤0.1%individual;

≤0.01%CH2CN

Complies

Related Peptide

Total Impurity ≤ 2.0%

Largest Single Impurity ≤ 1.0%

TI =0.41%

LSI =0.25%

Peptide Content:

Not Less than 85.0%

87.7%

Water (K.F.):

Not more than 5%

4.2%

Acetate acid:

Not more than 10%

8.1%

Bacterial Endotoxins

Not more than 50IU/mg

Complies


Usage


Function and Usage of Liraglutide 204656-20-2

1、 Type 2 diabetes
Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:

·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.

·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).

·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.

·         Liraglutide lowers blood triglyceride levels.

2、Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

rhodiola rosea extract manufacturers
RHODIOLA ROSEA EXTRACT
Salidroside 3-5%, Rosavins 3-5%, Rosavin 2% up
ARTEMISIA ARGYI EXTRACT Supplier -Sinoway
ARTEMISIA ARGYI EXTRACT
Isocyanine 0.8%-2.4%; Chamomile 0.25%-0.75%
PALMITOYLETHANOLAMIDE
PALMITOYLETHANOLAMIDE (PEA) 544-31-0
Product Information Product name Palmitoylethanolamide (PEA) Molecular Formula C18H37NO2 CAS No. 544-31-0 Quality Standard 98% up(Micronized Grade), Food grade, Cosmetic grade Appearance White powder COA of Palmitoylethanolamide (PEA) Testing Items Specifications Results Appearance Fine Powder Compiles Color White to Off-white Compiles Identification Positive Compiles Heavy Metals NMT 10 ppm Compiles Arsenic(As2O3) NMT 1 ppm Compiles Sulfate(SO4) NMT 0.040% Compiles Iron(Fe) NMT 10 ppm Compiles Chloride(Cl) NMT 0.020% Compiles Solvent Residual Meeting USP Standard Compiles Total Plate Count 10,000 cfu/g Max Compiles Yeast & Mold 300 cfu/g Max Compiles Coliforms 10 cfu/g Max Compiles E. Coli Negative/ 10g Negative Salmonella sp. Negative/ 25g Negative Staph Aureus Negative/ 10g Negative Pseudomonas Negative/ 25g Negative Residue on ignition 0.1% Max 0.03% Particle size D(0.5): 3um D(0.569): 3um D(0.99): 10um D(0.995): 10um Excipients None Confirm Loss on Drying 1.0% Max 0.15% Assay (on dried base, GC) NLT 98% 98.75% Conclusion The product conforms to in-house standard Usage Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, belonging to the class of nuclear factor agonists. PEA is one of the most important endogenous painkilling and anti-inflammatory compounds and has been shown to effective for both acute and chronic pain. Because the substance acts as a natural painkiller, it is an excellent alternative for conventional medications that might cause side effects. Function: 1. Anti-Inflammatory and Analgesic 2. Improve the ability of immunity 3. Treated chronic pain 4. Treated epilepsy, cerebral ischemia and stroke 5. Treated Alzheimer's disease and Parkinson's disease
DASATINIB
DASATINIB 302962-49-8
USP26, EP, GMP , DMF
natural creosote
NATURAL CREOSOTE 8021-39-4
Natural phenol: 98.0% up by GC, Medical grade, JP14 / BPC1959
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact